FREMONT, Calif., July 19 /PRNewswire-FirstCall/ -- Abgenix, Inc.
(Nasdaq: ABGX) will hold a conference call on Tuesday, July 26, 2005, at 1:30
p.m. PT, 4:30 p.m. ET, to discuss second quarter financial results and to
provide an update on the company's antibody discovery, development, and
manufacturing activities. Bill Ringo, president and chief executive officer of
Abgenix, will host the call.
To participate in the teleconference, please dial 800-798-2884 fifteen
minutes before the conference begins. International callers should dial
617-614-6207. The pass code is 58063402. The call will also be webcast live at
http://www.abgenix.com. A replay of the call will be available until August 9, 2005,
on the company's website or by dialing 888-286-8010. International callers
should dial 617-801-6888. The replay participant code is 30198294.
About Abgenix
Abgenix is a biopharmaceutical company focused on the discovery,
development and manufacturing of human therapeutic antibodies. The company's
antibody development platform includes a leading technology and state-of-the-
art manufacturing capabilities that enable the rapid generation, selection and
production of high affinity, fully human antibody product candidates to a
variety of disease targets. Abgenix leverages its leadership position in human
antibody technology to build a diversified product portfolio through its own
development efforts and the establishment of collaborations with multiple
pharmaceutical and biotechnology companies. For more information on Abgenix,
visit the company's website at http://www.abgenix.com.
SOURCE Abgenix, Inc.
 back to top
Related links:
http://www.abgenix.com
CONTACT:
Greg Mann, Director, Corporate Communications
& Investor Relations, of Abgenix, Inc., +1-510-284-6566 or
+1-510-284-6605
|
